Why Your Prototype Isn’t Enough: Building the Development Path Investors Fund
If you’re a biomedical engineer with a working prototype, you probably feel like you’ve conquered the hardest part. The technology works. The concept is proven. Now you just need someone to write the check.
The numbers tell a different story. 75% of medical device startups fail. In many of those cases, the technology worked fine. What failed was the development path around it. Engineers who can’t show investors a credible roadmap from prototype to commercialization don’t get funded, no matter how impressive the device. And three-quarters of venture-backed companies never return cash to investors, which means the money behind most of these ventures disappears too.
So how do you turn your prototype into a fundable, compliant, investor-ready medical device without wasting time, money, or your shot at FDA approval? You stop engineering the device and start engineering the process.
The Prototype Trap
We see this pattern constantly at Concise Engineering. A talented engineer spends months (sometimes years) refining a prototype’s look and function. They bring in industrial designers, iterate on the form factor, and 3D-print version after version. Then they walk into an investor meeting expecting the prototype to speak for itself.
It rarely does.
Investors aren’t funding your prototype. They’re funding evidence that you understand the full path to market and that you’ve reduced the risks standing between your device and revenue. The prototype is one data point in that story, not the whole story.
The average cost to bring a 510(k) device from concept to market exceeds $31 million. More than 77% of that cost (roughly $24 million) goes to regulatory and FDA-related activities. The engineering you’re comfortable with accounts for only a fraction of the total investment. Industrial design without an engineering team executing on regulatory and risk requirements is, frankly, a waste of time. It may look like progress, but it extends your timeline without moving you closer to approval or funding.
Plan for the End, Not the Next Demo
If we could give one piece of advice to every engineer walking through our door, it would be this: plan for manufacturing and commercialization from day one, then work backward.
Too many engineers build for the next investor meeting instead of building for market launch. Investors can tell the difference. They want to see that you’ve mapped your regulatory pathway (510(k), De Novo, or PMA) and that you understand the timeline and cost implications of each. They want evidence of a reimbursement or payer strategy, because a device that’s cleared but not reimbursed is a device that doesn’t sell. And they want to know you’ve considered manufacturing feasibility early enough that you’re not redesigning for producibility after you’ve burned through your seed round.
We worked with a client who came to us after spending over a year on prototyping without ever considering their regulatory classification. That single oversight cost them six months of rework and a missed funding window. The device was solid. The planning wasn’t.
Build the Business Case Before You Build the Next Feature
Every engineer should be able to answer this question before their next investor conversation: why does anyone care about your device?
That sounds blunt, but it’s what investors are asking when they look at your TAM (total addressable market), SAM (serviceable addressable market), and SOM (serviceable obtainable market). Market sizing is a fundability requirement. If you can’t quantify who needs your device, how many of them exist, and what share you can realistically capture, you don’t have a business case. You have a science project.
Clinical need validation goes hand in hand with market sizing. Demonstrate that the health problem your device addresses is real and underserved. Then show how your device fits into existing clinical workflows and reimbursement structures.
One thing we encourage our clients to think about early is platform potential. Even if you’re focused on a single indication right now (and you should be, for regulatory simplicity), can your technology span multiple clinical areas over time? Investors love platform plays because they represent multiple revenue opportunities from a single core technology. The key is choosing your first indication strategically: pick the easiest regulatory path or the largest business opportunity, then expand from there.
The Work Nobody Wants to Do (But Investors Need to See)
Risk management. Usability testing. Biocompatibility. Sterilization validation. Electrical safety. Third-party testing. Documentation.
None of this is glamorous, and none of it is optional.
We find that engineers often treat these requirements as boxes to check at the end of development. That approach almost always backfires. These activities generate the evidence trail that regulators and investors use to evaluate your device. When you defer them, you’re creating blind spots in your submission and red flags in your pitch deck.
The competition for funding reinforces why this matters. Only about 15 to 20% of SBIR/STTR grant applications in medtech get approved, meaning roughly four out of five applicants walk away empty-handed. In one recent quarter, just 67 U.S. medtech financing rounds closed, raising $2.9 billion total. The companies that win those rounds are the ones who’ve done the unglamorous work of proving their development path is credible.
When we help clients prepare for funding rounds, a significant part of our work is making sure risk management, design controls, and documentation are in place early. That preparation shows investors you’re operating with real engineering rigor.
The Takeaway
You don’t need a better prototype. You need a better roadmap.
Validate the clinical need. Size the market. Map the regulatory pathway. Plan for reimbursement. Design with manufacturing in mind from the start. And document everything along the way. That sequence, executed with engineering discipline, is what separates the companies that get funded from the 75% that don’t.
If you’re unsure where you stand on any of these fronts, or if you’ve been focused on the device and haven’t built the development path around it yet, schedule a call with Justin. We’ll help you assess what you’ve done, identify what’s missing, and map the steps that turn your prototype into an investor-ready, FDA-credible medical device.
Justin Bushko
President, Concise Engineering
Next Steps
We hope you find this newsletter valuable and insightful.
If you have any questions, if you have feedback or would like to explore any specific topics further, please feel free to reach out to us.
Please email me at jbushko@concise-engineering.com or to book a call with me, click this link.
Stay tuned for future editions where we'll continue to share valuable information and industry updates.